Allies in the fight against antimicrobial resistance

8 May 2020

The University of Queensland’s Centre for Clinical Research (UQCCR), will partner with the Global Antibiotic Research and Development Partnership (GARDP) Foundation to identify evidence-based treatment options for patients with serious bacterial infections. 

UQCCR Director Professor David Paterson said the collaboration was a valuable opportunity to evaluate new and existing antibiotic treatments, with the goal of combating antimicrobial resistance.

“We are very pleased to combine UQCCR’s research expertise in antimicrobials and clinical trials with GARDP’s clinical expertise and sustainable access commitment,” he said.

“Collaborations like this help to ensure that cutting-edge clinical research has the best chance of generating potentially life-changing treatments for those who need it most.”

Approximately 700,000 people worldwide die of drug-resistant infections every year and this number is expected to increase significantly in the future. Serious bacterial infections, and in particular gram-negative bacterial infections, have been identified by the World Health Organisation as a global public health priority.

GARDP is a not-for-profit research and development organisation that addresses global public health needs by developing and delivering new or improved treatments, while ensuring their sustainable access.